Items Tagged ‘Early Stage I-II (A-B) Prostate Cancer’

October 3rd, 2016

Different Treatment Options Appear Equally Effective in Early Prostate Cancer

By

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10 years. Spread of cancer, however, was higher among those whose cancer was monitored until progression. These results were recently published […]

View full entry

Tags: active monitoring, early, Early Stage I-II (A-B) Prostate Cancer, News, Prostate Cancer, prostatectomy, PSA, radiation, regimen, surgery


April 25th, 2016

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer

By

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak with their healthcare providers if they experience any feelings of depression, as effective treatment […]

View full entry

Tags: adt, depression, Early Stage I-II (A-B) Prostate Cancer, News, Prostate Cancer, testosterone


February 22nd, 2016

Xtandi® Improves Survival in Advanced Prostate Cancer

By

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men […]

View full entry

Tags: bicalutamide, casodex, Early Stage I-II (A-B) Prostate Cancer, enzalutamide, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi


November 5th, 2015

Shorter Course of Radiation as Effective as Longer Course in Low-Risk Prostate Cancer

By

A shorter course of hypofractionated radiation therapy, a treatment in which larger doses of radiation are delivered over a shorter time period than conventional radiation, appears as effective as longer courses for men with low-risk prostate cancer. These results were recently presented at the 57th annual meeting of the American Society for Therapeutic Radiation (ASTRO). […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, hypofractionated radiation therapy, low-risk, News, Prostate Cancer


August 17th, 2015

Two-drug combination boosts survival in metastatic prostate cancer

By

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical trial led by a Dana-Farber Cancer Institute scientist. Patients who underwent six cycles of treatment with the chemotherapy […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, News, Prostate Cancer


August 5th, 2015

Oncotype DX Increases Use of Active Surveillance in Prostate Cancer Patients

By

Genomic Health, Inc. announced that Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test’s Genomic Prostate Score (GPS) in treatment planning resulted in greater recommendations and acceptance of active surveillance as initial management of prostate cancer in low and low-intermediate risk […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, News, oncotype, Prostate Cancer, surveillance


July 15th, 2015

More Men with Low-Risk Prostate Cancer Are Delaying Treatment until Progression

By

Increasingly more men with low-risk, early-stage prostate cancer appear to choose active surveillance (or watchful waiting) instead of treatment. As a result, they’re avoiding the risk of long-term side effects of treatment. These findings were reported in the Journal of the American Medical Association. The treatment of early-stage prostate cancer with low risk of progression […]

View full entry

Tags: active surveillance, Early Stage I-II (A-B) Prostate Cancer, early-stage, low-risk, News, Prostate Cancer, side effects, treatment, watchful waiting


December 10th, 2014

Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations

By

CancerConnect News: Genomic Health, Inc. today announced results from two studies of the Oncotype DX® prostate cancer test demonstrating its value in low- and intermediate-risk prostate cancer to enable physicians and patients to avoid over- and under-treatment of the disease.  Both studies were presented, December 3, at the Society of Urologic Oncology (SUO) Annual Meeting, in […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, News, oncotype, Prostate Cancer, risk, treatment


November 18th, 2014

New Survey Reveals Alarming Lack of Understanding of Prostate Cancer

By

(OMNI-CancerConnect) In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, News, Prostate Cancer


November 11th, 2014

American Society of Clinical Oncology Endorses AUA/ASTRO Guidelines on the Use of Radiation Treatment After Prostatectomy

By

The American Society of Clinical Oncology (ASCO) issued an endorsement of the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guidelines on the use of adjuvant and salvage radiotherapy after prostatectomy, which was based on a systematic review of medical literature. The guideline recommends that “physicians discuss the role of radiation therapy with patients […]

View full entry

Tags: asco, astro, aua, Early Stage I-II (A-B) Prostate Cancer, News, Prostate Cancer, radiation therapy


October 13th, 2014

Radiation Therapy Benefits Selected Patients With Node-Positive Prostate Cancer

By

According to a recent report published in The Journal of Clinical Oncology, men with advanced prostate cancer involving the lymph nodes may benefit from treatment with radiation in addition to hormonal therapy. Prostate cancer is the most commonly diagnosed cancer (other than skin cancer) in U.S. men. Each year, more than 240,000 men are diagnosed […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, lymph node, News, Prostate Cancer, radiation therapy


October 1st, 2014

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients

By

REDWOOD CITY, Calif., Sept. 29, 2014 – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences’ (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, genomics, News, oncotype, Prostate Cancer


September 29th, 2014

Advances in Genomic Testing-What you Need to Know

By

Q: What is genomic testing? A: Genomic testing looks at a group of genes and their varying levels of expression. This gene expression or activity can characterize how genes interact with one another and predict the behavior of certain tissues within the body. This is in contrast to genetic testing, which looks at a specific change […]

View full entry

Tags: Adjuvant (I-III, A-C) Colon Cancer, Breast Cancer, Colon Cancer, Early Stage I-II (A-B) Prostate Cancer, General, genomics, News, Other News Topics (not Types of Cancer), Prostate Cancer, Stage I Node Negative Breast Cancer


September 11th, 2014

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives

By

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs) that support them. The majority (64 percent) of patients surveyed report that their prostate cancer diagnosis […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, quality of life, Refactory/Recurrent Prostate Cancer


August 11th, 2014

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test

By

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer.  This study validated the Oncotype DX prostate cancer […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, News, oncotype, oncotype dx, Prostate Cancer, risk recurrence